Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Jonathan Ian SilverbergMelinda J GooderhamAmy S PallerMette DeleuranChristopher G BunickLinda F Stein GoldDirk-Jan HijnenBrian M CalimlimWan-Ju LeeHenrique D TeixeiraXiaofei HuShiyu ZhangYang YangAyman GradaAndrew M PlattDiamant ThaҫiPublished in: American journal of clinical dermatology (2024)
ClinicalTrials.gov identifiers NCT03569293 (13 August 2018) and NCT03607422 (27 July 2018).